1.Ross JS, Fletcher JA. HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol 1999; 112(suppl.1): s53-s67. 2.Ménard S, Tagliabue E, Campiglio M, Pupa SM. Role of HER2 gene overexpresion in breast carcinoma. J Cell Physiol 2000; 182: 150-162. 3.Borg A, Baldertorp B, Ferno M, Killander D, Olsson H, Ryden S, Sigurdsson H. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994; 81: 137-144. 4.Carlomagno C, Perrone F, Gallo C, de Laurentis M, Lauria R, Morabito A, Pettinato G, Panico L, D‘Antonio A, Bianco AR, De Placido S. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 1996; 14: 2702-2708. 5.Yu D, Hung M-Ch. Role of erbB2 in breast cancer chemosensitivity. BioEssays 2000; 22: 673-680. 6-Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 1997; 10: 720-727. 7-Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamos DJ. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651-3664. 8-Kakar S, Puangsuvan N, Stevens JM, Serenas R, Mangan G, Sahai S, Mihalov ML. HER-2/neu assessment in breast cancer by immunohistochemistry and correlation with survival. Mol Diagnosis 2000; 5:199-207 9-Valeron PF, Chirino R, Vega V, Falcon O, Rivero JF, Torres S, Leon L, Fernandez L, Pestano J, Diaz Chico B, Diaz Chico JC. Quantitative analysis of p185 (HER-2/neu) protein in breast cancer and its association with other prognostic factors. Int J Cancer 1997; 74: 175-179. 10-Koscielny S, Terrier P, Daver A, Wafflart J, Goussard J, Ricolleau G, Delvincourt C, Delaure JC. Cuantitative determination of c-erbB-2 in human breast tumors: potential prognostic significance of low values. Eur J Cancer 1998; 34: 476-481. 11-Bermont L, Algros MP, Baron MH, Adessi GL. Relevande of p185 HER-2/neu oncoprotein quentification in human primary breast carcinoma. Breast Cancer Res 2000; 63: 163-169. 12-Eppenberger-Castori S, Kueng W, Benz C, Rosmarie C, Varga Z, Bannwart F, Fink D, Dieterich H, Hohl M, Müller H, Paris K, Schoumacher F, Eppenberger U. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001; 19: 645-656. 13-Dittadi R, Catozzi L,Gion M, brazzale A, Capitanio G, Gelli MC, Menegon A, Gardini G, Malagutti R, Piffanelli A. Comparison between Western blotting, immunohistochemical and ELISA assay for 185neu quentitation in breast cancer specimens. Anticancer Res 1993; 13: 1821-1824. 14-Cuny M, Simony-Lafontaine J, Rouanet P, Grenier J, Valles H, Lavaill R, Louason G, Causse A, Lequeix N, Thierry C, Jeanteur P, Theillet C. Quantification of ERBB2 protein expression in breast cancer: three levels of expression defined by their clinico-paphological correlations. Oncol Res 1994; 6: 169-176. 15-Pifanelli A, Dittadi R, Catozzi L, Gion M, Capitanio G, Gelli MC, Brazzale A, Malagutti R, Pelizzola D, Menegon A, Giovannini G, Gardini G. Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters. Breast Cancer Res 1996; 37: 267-276. 16-Sugano K, Ushiama M, Fukutomi T, Tsuda H, Krroh T, Ohkura H. Combined measurement of the c-erbB-2 protein in breast carcinoma tissues and sera is useful as a sensitive tumor marker for monitoring tumor relapse. Int J Cancer 2000; 89: 329-336. 17-Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in the immunohistochemical studies of oncogene expression. Cancer Res 1994; 54: 2771-2777.
|